Radiance® by LumaCyte delivers real time, label free, single cell analytics for quantitative cellular characterization — enabling deeper insights into cell health, predictive viability, cellular response metrics, and functional potency.
This advanced cellular PAT platform is redefining biomanufacturing by helping production scientists rapidly assess the quality of cellular starting materials and precisely optimize critical workflows in the production of complex lifesaving biotherapeutics. Powered by robust multivariate and multiattribute analytics, Radiance® applies machine learning to deliver predictive insights with Time to Result (TTR) in minutes—giving teams the speed and intelligence needed to make informed decisions, faster.
At its core is Laser Force Cytology™ (LFC™)—a proprietary technology that measures optical and fluidic forces acting on cells within a microfluidic environment to reveal intrinsic biochemical and biophysical changes. Subtle shifts in cell behavior are precisely captured through the Radiance® automated workflow, enabling developers to monitor product quality attributes in-process and via offline release and potency assays.
Manufacturing success and consistency are foundational to FDA approvals. Radiance® empowers developers and sponsors with advanced GMP analytics to proactively mitigate risk, streamline technical transfer, and ensure robust comparability across clinical and commercial scale. Through continuous monitoring of critical process parameters and product quality attributes, Radiance® supports both FDA-aligned real time release testing strategies within the broader CMC framework and potency assurance approaches designed specifically for cellular and gene therapies. By delivering predictive insights through multiattribute analytics, Radiance® helps production teams drive process reliability, therapeutic integrity, and lifecycle confidence.